Paige, Sonrai Form Partnership to Harness AI for Precision Medicine R&D

Artificial intelligence (AI) precision medicine company Sonrai Analytics and next-generation AI technology specialist Paige have announced a strategic partnership that both parties say will allow researchers, pathologists, and clinicians in the bio/pharmaceutical space to harness emerging AI capabilities for R&D of precision medicines (1).

The announcement, made on April 16, 2025, further clarified that Paige’s state-of-the-art foundation models would be integrated with Sonrai’s intuitive cloud-based data analysis and bioinformatics platform (1).

“We are thrilled to partner with Paige to unlock new possibilities for biopharma researchers and clinicians,” Darragh McArt, CEO and founder of Sonrai Analytics, said in a press release (1). “By combining our Sonrai Discovery platform with Paige’s foundation models, we are making AI and machine learning [ML] more accessible, enabling researchers to extract deeper insights from their data and accelerate precision medicine breakthroughs.”

Sonrai Discovery is Sonrai Analytics’ flagship product, which has the aim of expediting identification and development of therapeutic targets through the use of AI, thus improving patient outcomes (1).

"Our goal has always been to build best-in-class AI technology that is accessible to as many users as possible,” Razik Yousfi, CEO and CTO at Paige, said in the press release (1). “Our partnership with Sonrai further drives this vision, providing a wider audience of researchers access to Paige's foundation models through the Sonrai Discovery platform. This will ultimately accelerate pharma research and discovery globally, accelerating the new wave of AI-driven biomarkers in cancer and other diseases.”

AI has been a hot topic for the bio/pharmaceutical industry in the early part of 2025. AI-based computational models will be a part of FDA’s new approach to reducing, refining, or replacing animal testing in the development of monoclonal antibody therapies (2). Siemens has an agreement in place to acquire the life sciences R&D software provider Dotmatics, a move that extends Siemens’ AI-powered product lifecycle management portfolio into the life sciences market (3).

In March 2025, survey data released jointly by The Pistoia Alliance and the Copyright Clearance Center suggested that agentic AI is identified by pharmaceutical industry leaders as the technology that will have the most significant impact on the field in the next two to three years (4).

Alexander Seyf, CEO and co-founder of Autolomous, told Pharmaceutical Technology® Group that AI can and should be used as another tool in the toolbox, but can’t be the solution to everything.

“AI and ML can help us to do the leg work, but the main work is going to need to be done by our own brain, by human beings,” Seyf said in an April 2025 interview (5).

Similarly, at INTERPHEX 2025, Peter Sarvey, head of Sales for Automation NTH, illustrated an example of how AI can assist, if not take over, processes that were formerly entirely performed by humans.

“There are a lot of inspections that previously were done manually, because it's not a simple pattern match for if this medical device or this pharmaceutical component is a reject,” Sarvey said (6). “Now we can teach the AI what a good part looks like, what a bad part looks like, and then over time, shift that area too, all in the nature of increasing throughput and decreasing yield loss.”

The full video interviews with Seyf and Sarvey can be viewed on the Pharmaceutical Technology® website.

References

1. Sonrai Analytics. Sonrai and Paige Partner to Bring Advanced Machine Learning Capabilities to Biopharma. Press Release. April 16, 2025.
2. FDA. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. Press Release. April 10, 2025.
3. Siemens. Siemens Acquires Dotmatics to Extend AI-Powered Software Portfolio to Life Sciences. Press Release. April 2, 2025.
4. The Pistoia Alliance. Life Science Professionals say Agentic AI to Have Most Impact in Next 2-3 Years, but 51% Cite Resistance to Change as Biggest Barrier to Innovation. Press Release. April 3, 2025.
5. Thomas, F. and Haigney, S. Industry Outlook 2025: Technology as a Supporting Element. PharmTech.com, April 14, 2025.
6. Lavery, P. and Haigney, S. INTERPHEX 2025: AI and Automation in Pharma. PharmTech.com, April 2, 2025.